Releases
MNPR
0.6810
-7.60%
-0.0560
  • All
  • Financials
  • Insiders
More
Webull provides the latest Monopar Therapeutics Inc (MNPR) stock and general news. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of therapeutics designed to extend life or improve the quality of life for cancer patients. The Company's pipeline consists of Validive, camsirubicin, MNPR-101, MNPR-101 RIT and MNPR-202. Its lead product candidate, Validive is under Phase IIb/III clinical trial for the prevention of chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (VOICE trial). The Company also commenced a United States-based open-label, Phase Ib clinical trial of camsirubicin for the treatment of advanced soft tissue sarcoma (ASTS). Its three preclinical programs include MNPR-101, MNPR-101 RIT and MNPR-202. Its MNPR-101 is a humanized monoclonal antibody to the urokinase plasminogen activator receptor (uPAR), for use as a radiopharmaceutical in advanced cancers. Its MNPR-101 RIT which continues development for the treatment of cancer and severe COVID-19 in collaboration.